Cat.#: ASSD-112
| Description | Propidium iodide (PI) is a widely used red-fluorescent intercalating agent that binds and labels nucleic acids. When bound to the nucleic acids, its fluorescence is enhanced 20- to 30-fold. Frequently used with Oxazole Yellow (YP1) when staining for apoptotic and necrotic cells as apoptotic cells remain impermeant to propidium iodide but permeable to Oxazole Yellow (YP1). |
| Synonyms | PI |
| Size | 1 mL |
| Applications | Flow cytometry, fluorescent microscopy and confocal laser scanning microscopy. Propidium iodide is membrane impermeant and is therefore frequently used to selectively identify dead cells and is commonly used in flow cytometry to evaluate cell viability. |
| Chemical Name | 2,7-Diamino-9-phenyl-10 (diethylaminopropyl)-phenanthridium iodide methiodide |
| Molecule Weight | 668.39 |
| Molecular formula | C27H34I2N4 |
| CAS Number | 25535-16-4 |
| PubChem identifier | 104981 |
| MDL Number | MFCD00011921 |
| Purity | >97% |
| Excitation | 535 nm |
| Emission | 617 nm |
| Storage | Store at 4° C |
| Shipping | Shipped at 4°C |
| Important | We strongly recommend storing this solution away from light. |
| Cat.# | Name | Size | Price |
|---|---|---|---|
| ASSD-202 | 5(6)-Carboxytetramethylrhodamine (AC202) | 100 mg, 250 mg | inquiry |
| ASSD-219 | Tetramethylrhodamine-6-maleimide (AC219) | 5 mg | inquiry |
| ASSD-129 | Fluorescent 5-HT1A antagonist [NAN-190] (AC129) | 50 μg | inquiry |
| ASSD-136 | LUF7445/A2A antagonist (AC136) | 50 μg | inquiry |
| ASSD-161 | Methylene Blue (AC161) | 50 mg, 1 g | inquiry |
| ASSD-107 | Modified Mayer's Hematoxylin (AC107) | 125 mL, 250 mL, 2×250mL | inquiry |
| ASSD-224 | Antifade Fluorescence Mounting Medium with DAPI (aqueous) (AC224) | 10 mL | inquiry |
| ASSD-118 | BrdU (5-Bromo-2′-deoxyuridine) (AC118) | 200 mg, 100 mg, 1 g, 5g | inquiry |
| ASSD-198 | NHS-5(6)Carboxyrhodamine (AC198) | 25 mg | inquiry |
| ASSD-146 | Pyronin Y (AC146) | 1 g, 5g | inquiry |
Ace Therapeutics is a global leading provider of stroke research services. We are committed to accelerating progress in stroke research and drug development.